Contact
      Please use this form to send email to PR contact of this press release:
      
      Human medicines European public assessment report (EPAR): Ximluci, ranibizumab, Wet Macular Degeneration;Macular Edema;Diabetic Retinopathy;Diabetes Complications, Date of authorisation: 09/11/2022, Revision: 1, Status: Authorised
    
      TO: